U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. DCA Inc. dba Beacon Prescriptions - 525833 - 09/22/2021
  1. Warning Letters

CLOSEOUT LETTER

DCA Inc. dba Beacon Prescriptions MARCS-CMS 525833 —

Delivery Method:
VIA Electronic Mail
Reference #:
3005823862
Product:
Drugs
Recipient:
Recipient Name
Annik S. Chamberlin
Recipient Title
PharmD
DCA Inc. dba Beacon Prescriptions

690 North Main Street
Southington, CT 06489-2529
United States

Issuing Office:
OPQO Division I / New Jersey District

United States

(973) 331-4900

Dear Dr. Chamberlin:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [WL #525833], dated June 1, 2017. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

If you have any questions, contact Compliance Officer Juan Jimenez at orapharm1_responses@fda.hhs.gov; and juan.jimenez@fda.hhs.gov. Please identify correspondence with FEI # 3005823862.

Sincerely,
Diana Amador-Toro
Program Division Director/District Director
U.S. Food and Drug Administration
OPQO Division I / New Jersey District
Diana Amadortoro
-S
Digitally signed by Diana Amador-toro -S
DN: c=US, o=U.S. Government, ou=HHS,
ou=FDA, ou=People,
0.9.2342.19200300.100.1.1

Back to Top